menu
    • menu
    [{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alter Pharma group \/ Hyloris","highestDevelopmentStatusID":"12","companyTruncated":"Alter Phar.."},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"AchE","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Alter Pharma group \/ Alter Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Alter Phar.."},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Magnesium Sulfate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alter Pharma group \/ Alter Pharma Group","highestDevelopmentStatusID":"12","companyTruncated":"Alter Phar.."}]

    Find Clinical Drug Pipeline Developments & Deals by Alter Pharma group

    Menu

    Alter Pharma group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Magnesium Sulfate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Athenex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magn...

                            Details : Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. It reduces striated muscle contractions and blocks peripheral neuromuscular transmission ...

                            Product Name : Magnesium Sulfate-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Magnesium Sulfate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Athenex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Milla Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma...

                            Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.

                            Product Name : Pyridostigmine Bromide-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Milla Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Alter Pharma group

                            Costa Rica arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group

                            Details : Maxigesic IV (a unique combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion) is a novel, patented, non-opioid pain treatment, and is being commercialised by Hyloris’ partner AFT...

                            Product Name : Maxigesic IV

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 24, 2021

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth